AKR1C3 and malignant colon neoplasm: In colon cancers, studies reported that the up-regulated expression of AKR1B10, AKR1C1, AKR1C2 and AKR1C3 contributed to chemotherapeutic drug resistance indirectly, by reducing oxidative stress generated by these chemotherapeutic agents (Deng et al., 2004).